Phase 2Recruiting
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)
- Sponsor
- Merck Sharp & Dohme LLC (Industry)
- Enrolment
- 250 planned
- Conditions
- Malignant Neoplasm
- Interventions
- Opevesostat; Fludrocortisone/ Fludrocortisone acetate; Dexamethasone/Dexamethasone acetate; Rescue Medications; Fulvestrant; Exemestane; Megestrol acetate/Medroxyprogesterone acetate; Tamoxifen; Letrozole
- Ages
- adults, older adults
- Registry
- NCT06979596
From the registry
Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid hormones. Researchers will compare MK-5684 to the standard treatments for each cancer type in this study. The goal of this study is to learn if people who receive MK-5684 live longer without the cancer growing or spreading compared to people who receive a standard treatment.
Primary outcomes
- Progression-Free Survival (PFS) - All Cohorts